» Articles » PMID: 38310350

Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia

Overview
Journal Am J Case Rep
Specialty General Medicine
Date 2024 Feb 4
PMID 38310350
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The patient was asymptomatic. A workup was initiated for essential thrombocythemia, and she was tested for JAK2 V617F mutation using an allele-specific polymerase chain reaction (AS-PCR) test in peripheral blood, which came back positive. The variant allele frequency was 2%. She underwent a bone marrow biopsy, and next-generation sequencing (NGS) showed a CALR mutation. A 52 bp deletion-type mutation was detected in the CALR gene on exon 9, with a variant allele frequency of 7%. The NGS did not detect JAK2 mutation due to its low sensitivity. She was started on aspirin alone as she was less than 60 years old and had no history of thrombotic events. The patient has been following up with the hematology clinic for the last 2 years and has not had any thrombotic events. CONCLUSIONS We propose that in patients with a low JAK2 V617 allele variant, testing for other driver mutations should be performed. In our patient, JAK2 mutation could be clonal hematopoiesis of indeterminate potential; therefore, the dominant mutation (CALR) would determine the disease phenotype.

References
1.
Cross N . Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011; 2011:208-14. DOI: 10.1182/asheducation-2011.1.208. View

2.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan A, Milosevic J . JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013; 123(10):1544-51. PMC: 3945864. DOI: 10.1182/blood-2013-11-539098. View

3.
Campbell P, Green A . The myeloproliferative disorders. N Engl J Med. 2006; 355(23):2452-66. DOI: 10.1056/NEJMra063728. View

4.
Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J . Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. J Mol Diagn. 2016; 19(1):92-98. DOI: 10.1016/j.jmoldx.2016.08.006. View

5.
Kang M, Choi H, Lee J, Choi Y, Choi H, Shin J . Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016; 7(35):57036-57049. PMC: 5302971. DOI: 10.18632/oncotarget.10958. View